Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients

Background: Gefitinib (ZD 1839, Iressa) is a new anticancer agent; more specifically, it is a selective epidermal growth factor receptor tyrosine kinase inhibitor that is, widely used for various solid cancers, including lung cancer. Cutaneous adverse reactions induced by gefitinib have recently been reported; however, not much on this topic has been reported in the Korean literature. Method: We studied cutaneous adverse reactions of gefitinib in 23 patients who suffered with non-small cell lung cancer at Chonnam National University Hwasun Hospital from October 2004 to September 2005. Result: The patients ranged from 23-72 years old, and there were 17 patients with adenocarcinoma, 5 with squamous cell carcinoma and 1 with bronchioloalveolar carcinoma. The most common adverse reaction was acneiform eruptions in 15 patients (65.2%). This reaction appeared within 2 months after medication, and it didn't correlate with the therapeutic response and tumor type. Pruritus was the second most common reaction (39.1%), which was mild and generalized, especially around eyelid area. Xerosis (26.1%), exfoliation on palm and sole (21.7%), and paronychia (21.7%) followed. Hair breakage and intertrigo were rare adverse reactions. Conclusion: Various cutaneous adverse reactions were observed in patients with non-small cell lung carcinoma after gefitinib treatment. The skin complications could be alleviated with dermatologic consultations and treatments, skin complications could be alleviated. (Tuberc Respir Dis 2006; 61: 150-156)

keywords: Gefitinib, Cutaneous adverse reactions, Lung cancer.

Reference

Ranson M, (2004) Geftinib,a novel,orally administered agent for the treatment of cancer,

Forsythe B, (2004) Overview of the tolerability of geftinib clinical experience in non-small-cell lung cancer,

Kim YJ, (2004) A case of acneiform skin eruption associated with ZD1839(Iressa),

Bae EY, (2004) A case of paronychia,acneiform eruption and dry skin induced bu Iressa,

Yu DK, (2004) A case of hair change and acneiform eruption induced by ZD1839(Iressa),

Jang YH, (2005) Study of clinical features of cutaneous side effects associated with ZD 1839,

Park JH, (2005) Cutaneous adverse effects associated with Iressa(Geftinib)medication,

Arteaga CL, (2001) Tyrosine kinase inhibitors-ZD1839(Iressa),

Kris M, (2003) Efficacy of geftinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer,

10.

Albanell J, (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD 1839 in skin from cancer patients:histopathologic and molecular consquencies of receptor inhibition,

11.

Lee MW, (2004) Cutaneous side effects in non-small cell lung cancer patients treated with Iressa an inhibitor of epidermal growth factor,

12.

Kimyai-Asadi A, (2002) Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors,

13.

Segaert S, (2005) Clinical signs,pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors,

14.

Jacot W, (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors,

15.

van Doorn R, (2002) Follicular and epiermal alterations in patients treated with ZD1839(Iressa)an inhibitor of the epidermal growth factor receptor,

16.

Cohen EE, (2003) Phase II study trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,

17.

Mohamed MK, (2005) Skin rash and good performance status predict improved survival with geftinib in patients with advanced non-small cell lung cancer,

18.

Peus D, (1997) EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation,

바로가기메뉴

Article Contents

Vol.61 No.2

Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients

Abstract

Reference

Tuberculosis & Respiratory Diseases